MedTrace Logo

Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System

NCT00837993 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 241

Last updated 2012-12-21

No results posted yet for this study

Summary

Primary Objective:

* To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system.

Secondary Objective:

* To determine the overall and progression-free survival of patients with serous carcinoma of the ovary treated on GOG protocol 158 when reclassified according to tumor grade (low vs. high).

Tertiary Objective:

* To correlate histologic grade with other prognostic factors.

Conditions

Sponsors & Collaborators

  • Gynecologic Oncology Group

    collaborator NETWORK

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Diane C. Bodurka, MD, BS · UT MD Anderson Cancer Center

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837993 on ClinicalTrials.gov